Lynparza (olaparib), a product of Fortune 500 pharmaceutical company Merck and Fortune 500 European company AstraZeneca, showed significant improvements in overall survival in people with BRCA mutated (gBRCAm), HER2-negative high-risk early breast cancer, clinical trial 2024 data suggest.
Jaime Grajales Benjumea—Getty Images
